Cover Image
市場調查報告書

皮膚感染疾病的開發中產品分析

Skin Infections - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 255953
出版日期 內容資訊 英文 183 Pages
訂單完成後即時交付
價格
Back to Top
皮膚感染疾病的開發中產品分析 Skin Infections - Pipeline Review, H1 2014
出版日期: 2014年06月15日 內容資訊: 英文 183 Pages
簡介

皮膚感染疾病和皮膚炎是不同的疾病,但其共通點是會伴隨著皮膚發炎。伴隨皮膚感染症的炎症被稱呼為感染性皮膚炎(infective dermatitis)。真菌·細菌·病毒等是皮膚感染的主要原因。感染症的治療法是使用抗生物質的局部療法。

本報告提供全球各國治療皮膚感染疾病的開發中產品開發狀況分析,提供開發中產品的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

皮膚感染疾病概要

治療藥的開發

  • 皮膚感染疾病用開發中產品:概要
  • 皮膚感染疾病用開發中產品:比較分析

各企業開發中的皮膚感染疾病治療藥

大學/研究機關研究中的皮膚感染疾病治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

皮膚感染疾病治療藥:開發中的產品一覽(各企業)

皮膚感染疾病治療藥:研究中的產品一覽(大學/研究機關別)

參與皮膚感染疾病治療藥開發的企業

  • 武田藥品工業
  • Amorepacific Corporation
  • 富山化學工業
  • Foamix Ltd.
  • Anacor Pharmaceuticals, Inc.
  • Lytix Biopharma AS
  • MGB Biopharma Limited
  • Pergamum AB
  • Biota Pharmaceuticals, Inc.

皮膚感染疾病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 分子的各類型
  • 各治療分類

藥物簡介

  • ceftaroline fosamil
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ozenoxacin
  • DPK-060
  • LTX-109
  • minocycline
  • AN-2718
  • PAC-14028
  • RX-02
  • Gyrase Program
  • 基於殺菌性毒素的縮多氨酸
  • MGB-BP-3
  • acALY18
  • 為了抑制ADAM10造成的皮膚·肺感染疾病用的單株抗體
  • 細菌性Lipopeptides
  • 細菌感染疾病用醫藥品

皮膚感染疾病治療藥:最新的藥物簡介

皮膚感染疾病治療藥:開發暫停的產品

皮膚感染疾病相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5101IDB

Summary

Global Markets Direct's, 'Skin Infections - Pipeline Review, H1 2014', provides an overview of the Skin Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Skin Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Skin Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Skin Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Skin Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Skin Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Skin Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Skin Infections Overview
  • Therapeutics Development
    • Pipeline Products for Skin Infections - Overview
    • Pipeline Products for Skin Infections - Comparative Analysis
  • Skin Infections - Therapeutics under Development by Companies
  • Skin Infections - Therapeutics under Investigation by Universities/Institutes
  • Skin Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Skin Infections - Products under Development by Companies
  • Skin Infections - Products under Investigation by Universities/Institutes
  • Skin Infections - Companies Involved in Therapeutics Development
    • GlaxoSmithKline plc
    • Takeda Pharmaceutical Company Limited
    • Melinta Therapeutics, Inc
    • The Medicines Company
    • Toyama Chemical Co., Ltd.
    • Wockhardt Limited
    • Paratek Pharmaceuticals, Inc.
    • CrystalGenomics, Inc.
    • Debiopharm International S.A.
    • Bharat Biotech International Limited
    • MerLion Pharmaceuticals Pte Ltd
    • Foamix Ltd.
    • Anacor Pharmaceuticals, Inc.
    • Destiny Pharma Ltd.
    • Nabriva Therapeutics AG
    • Atox Bio Inc.
    • Cempra, Inc.
    • Cellceutix Corporation
    • Tetraphase Pharmaceuticals Inc.
    • Lytix Biopharma AS
    • Durata Therapeutics, Inc.
    • MGB Biopharma Limited
    • Pergamum AB
    • Furiex Pharmaceuticals, Inc.
    • Microbion Corporation
    • Biota Pharmaceuticals, Inc.
    • Lipid Pharmaceuticals ehf.
    • Dong-A Socio Holdings Co Ltd
  • Skin Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • dalbavancin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oritavancin disphosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ceftaroline fosamil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tedizolid phosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ozenoxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-1322322 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AFN-1252 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lysostaphin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omadacycline tosylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brilacidin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • radezolid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CG-400549 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fusidic acid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LTX-109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • minocycline - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AB-103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avarofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WCK-2349 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2140944 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-7013 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-2718 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Bismuth ethanedithiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1450 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Skin Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPD-207 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-04 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gyrase Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CaTx-II - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGB-BP-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • acALY18 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Skin and Soft Tissue and Community Acquired Pneumonia Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies Targeting ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DBAF-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 50S RNA for Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KBP-7072 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • siderocillin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • finafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides to Activate TLR-2 for Oncology and Dermatology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DHFR for cSSSI - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPK-060 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eravacycline - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Skin Infections - Recent Pipeline Updates
  • Skin Infections - Dormant Projects
  • Skin Infections - Discontinued Products
  • Skin Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 29, 2013: Durata Therapeutics Announces Presentation Of New Data Demonstrating In Vitro Potency Of Dalbavancin Against Bacterial Pathogens At 23rd Annual ECCMID Meeting
      • Dec 15, 2011: Rib-X Reports Positive Top-Line Data From Phase IIb Study Of Delafloxacin In Patients With Acute Bacterial Skin And Skin Structure Infections
      • Sep 15, 2011: Nabriva Therapeutics Presents Extended Phase II Results For Pleuromutilin Antibiotic BC-3781
      • Jun 06, 2011: Durata Therapeutics Announces Successful Production Of Clinical Supplies Of Dalbavancin
      • Apr 18, 2011: Nabriva Reports Positive Results from Phase II Trial Of Pleuromutilin Antibiotic BC-3781 In ABSSSI
      • Apr 18, 2011: Durata Therapeutics Initiates Phase III Study Of Dalbavancin For Treatment Of Acute Bacterial Skin And Skin Structure Infections
      • Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva
      • Nov 29, 2010: The Medicines Company Reaches Agreement With FDA On SPA For Oritavancin Phase III Trials
      • Sep 07, 2010: Forest Receives FDA Advisory Committee Approval For Ceftaroline Fosamil For Treatment Of CABP And cSSSI
      • Sep 01, 2010: Lytix Biopharma Receives Hungarian Approval To Start Phase IIa Clinical Trial With Lytixar In Gram Positive Skin Infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Skin Infections, H1 2014
  • Number of Products under Development for Skin Infections - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Development by Companies, H1 2014 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Development by Companies, H1 2014 (Contd..1)
  • Products under Development by Companies, H1 2014 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2014
  • Skin Infections - Pipeline by GlaxoSmithKline plc, H1 2014
  • Skin Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014
  • Skin Infections - Pipeline by Melinta Therapeutics, Inc, H1 2014
  • Skin Infections - Pipeline by The Medicines Company, H1 2014
  • Skin Infections - Pipeline by Toyama Chemical Co., Ltd., H1 2014
  • Skin Infections - Pipeline by Wockhardt Limited, H1 2014
  • Skin Infections - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014
  • Skin Infections - Pipeline by CrystalGenomics, Inc., H1 2014
  • Skin Infections - Pipeline by Debiopharm International S.A., H1 2014
  • Skin Infections - Pipeline by Bharat Biotech International Limited, H1 2014
  • Skin Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2014
  • Skin Infections - Pipeline by Foamix Ltd., H1 2014
  • Skin Infections - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014
  • Skin Infections - Pipeline by Destiny Pharma Ltd., H1 2014
  • Skin Infections - Pipeline by Nabriva Therapeutics AG, H1 2014
  • Skin Infections - Pipeline by Atox Bio Inc., H1 2014
  • Skin Infections - Pipeline by Cempra, Inc., H1 2014
  • Skin Infections - Pipeline by Cellceutix Corporation, H1 2014
  • Skin Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2014
  • Skin Infections - Pipeline by Lytix Biopharma AS, H1 2014
  • Skin Infections - Pipeline by Durata Therapeutics, Inc., H1 2014
  • Skin Infections - Pipeline by MGB Biopharma Limited, H1 2014
  • Skin Infections - Pipeline by Pergamum AB, H1 2014
  • Skin Infections - Pipeline by Furiex Pharmaceuticals, Inc., H1 2014
  • Skin Infections - Pipeline by Microbion Corporation, H1 2014
  • Skin Infections - Pipeline by Biota Pharmaceuticals, Inc., H1 2014
  • Skin Infections - Pipeline by Lipid Pharmaceuticals ehf., H1 2014
  • Skin Infections - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Skin Infections Therapeutics - Recent Pipeline Updates, H1 2014
  • Skin Infections - Dormant Projects, H1 2014
  • Skin Infections - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Skin Infections, H1 2014
  • Number of Products under Development for Skin Infections - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top